Ironwood to Pay $1B to Acquire VectivBio, Late-Stage Digestive Therapy

[{"selector":"#anim-c4ab87d6-1a5f-4590-a8fc-84e695b7d4ae","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9af20cd2-a417-44bf-a80d-8c789739de66","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Ironwood Pharmaceuticals will acquire VectivBio in a $1 billion cash deal.

[{"selector":"#anim-73ed20a6-95f8-4b3b-8901-944f2b5352c1","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. The acquisition will expand Ironwood's gastrointestinal drug portfolio.

[{"selector":"#anim-79ae80bd-9249-4fd8-b76b-bf40b244f2dc","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. VectivBio's most advanced product is apraglutide, being developed for short bowel syndrome with intestinal failure.

[{"selector":"#anim-9c53cece-173e-4c13-89af-8ce443329648","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. Short bowel syndrome affects around 18,000 adult patients in the U.S., Europe, and Japan.

[{"selector":"#anim-830d342b-d6ff-4ae3-aa98-444e9d3e22a4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. Apraglutide is being tested in a Phase III study involving weekly injections.

[{"selector":"#anim-aee76a0b-c446-4338-a68a-e4337375e9c7","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. Results from the Phase III study are expected by the end of the year.

[{"selector":"#anim-f9431109-6eb0-405e-8c9c-91cb63276e52","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Apraglutide is also being studied for acute graft-versus-host disease.

[{"selector":"#anim-9c378d3d-3e38-4af0-82c6-247df03bb8d8","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. VectivBio has other assets in the discovery and preclinical stages for various disorders.

[{"selector":"#anim-0a244f14-3813-4cd2-bf26-3d7822a6fdb4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. Ironwood will pay $17 per VectivBio share, a 43% premium to the stock's closing price.

[{"selector":"#anim-2c8b327d-a9df-47ea-a85b-1939c098068f","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. The deal is expected to close in the second half of 2023, pending regulatory approvals.

[{"selector":"#anim-4a0ff7aa-e4a8-4f2f-bee8-489c4b9345cf","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-8a121b87-5e7e-450a-893a-ce563139f71a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more